Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

ZVRA Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Zevra Therapeutics, Inc.NASDAQ: ZVRA

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense growth accelerates

Q1 FY2026 income tax expense of $6.91M rose 484.9% year over year, ahead of the -44.8% change in trailing-twelve-month income tax expense. Sequentially, it rose 1280.0% from the prior quarter.

Context

  • Income tax expense amounted to 3.2% of revenue in FY2025, down 61.9 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +484.9% holds above the trailing-twelve-month pace of -44.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.91M+1280.0% QoQ
Last fiscal yearDec 2025
$3.45M-77.6% YoY
LTMMar 2026
$9.18M-44.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+484.9%——
1 year-77.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
3.45M USD
Year-over-year change
-77.6%
4-year CAGR
+217.4%

Income Tax Expense vs competitors

How ZVRA compares with its peers on the latest reported figures

  • ZVRA's LTM Mar 2026 income tax expense of $9.18M is the 4th highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -44.8% is the 4th highest of 7, against a peer median of -33.1%.
  • Income tax expense amounts to 7.5% of revenue for ZVRA, versus a peer median of 1.4%.
ZVRA Competitors Peer median
Income Tax Expense for ZVRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$229.6M +14.5%+56.3%6.2%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$53.58M +116.0%—1.1%
ALKSAlkermes plcLTM Sep 2026$11.66M -81.5%+190.8%0.7%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$9.18M -44.8%—7.5%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55K -80.6%——
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$0 ———
GHRSGH Research PLCLTM Mar 2026$0 ———
ANROAlto Neuroscience, Inc.LTM Mar 2026$0 ———
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$0 ———
XENEXenon Pharmaceuticals Inc.LTM Sep 2026-$775K +77.0%+105.0%—
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-$13.58M -176.9%—1.6%
Peer median (excluding ZVRA) $0-33.1%+105.0%1.4%

Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.65M10.16M27.46M23.61M106.47M
Cost of Revenue2.06M222K2.95M7.42M16.48M
Gross Profit26.59M9.94M24.52M16.2M89.99M
Gross Margin92.8%97.8%89.3%68.6%84.5%
Research & Development10.16M19.8M39.81M42.1M12.74M
Selling, General & Admin8.7M15.04M35.09M54.87M77.62M
Operating Expenses18.86M52.5M74.12M103.2M94.22M
Depreciation & Amortization257K944K1.01M6.39M4.05M
EBITDA(7.89M)(25.53M)(43.54M)(76.4M)98.71M
EBITDA Margin-27.5%-251.2%-158.6%-323.6%92.7%
Operating Income7.73M(42.57M)(49.6M)(87M)(4.23M)
Operating Margin27.0%-418.9%-180.6%-368.5%-4.0%
Interest Income261K1.51M4.54M2.18M6.95M
Interest Expense376K335K1.5M7.35M7.98M
Other Income / Expenses(16.25M)15.76M3.56M(3.14M)90.91M
Income Before Tax(8.52M)(26.81M)(46.05M)(90.14M)86.68M
Pre-Tax Margin-29.7%-263.8%-167.7%-381.8%81.4%
Income Tax Expense34K(33K)015.37M3.45M
Net Income(8.56M)(26.77M)(46.05M)(105.51M)83.23M
Net Margin-29.9%-263.5%-167.7%-446.9%78.2%
EPS (Basic)(2.11)(0.78)(1.30)(2.28)1.40
EPS (Diluted)(2.11)(0.78)(1.30)(2.28)1.35
Weighted Avg Shares29.77M34.49M35.45M46.25M55.31M
Weighted Avg Shares (Diluted)29.77M34.49M35.45M46.25M57.26M

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Intrinsic Alpha fair value

Locked

Current Price

$9.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.